Journal
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
Volume 16, Issue 4, Pages 461-472Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/14737159.2016.1142374
Keywords
validation; clinical laboratory; hematologic malignancies; mutation; next-generation sequencing
Categories
Ask authors/readers for more resources
Targeted therapy based on mutational profiles is the current standard of practice for the management of patients with hematologic malignancies. Next-generation sequencing (NGS)- based analysis has been adopted by clinical laboratories for high-throughput mutational profiling of myeloid and lymphoid neoplasms. The technology is fairly novel and complex, hence both validation and test implementation in a CLIA-certified laboratory differ substantially from traditional sequencing platforms. Recently, organizations such as the American College of Medical Genetics, Centers for Disease Control and Prevention and College of American Pathologists have published principles and guidelines for NGS test development to ensure standardization of testing across institutions. Summarized here are the recommendations from these organizations as they pertain to targeted NGS-based testing of hematologic malignancies ('liquid tumors'), with particular emphasis on myeloid neoplasms.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available